13 research outputs found
Çukurova yöresindeki ailevi Akdeniz ateşi hastalarında MEFV geni 10.ekzon majör nokta mutasyonları sıklığının incelenmesinde arms ve PCR-RELP yöntemlerinin karşılaştırılması
TEZ4660Tez (Doktora) -- Çukurova Üniversitesi, Adana, 2003.Kaynakça (s. 43-48) var.xi, 48 s. ; 30 cm.
Sistemik lupus eritematozus ve romatoid artritte otoantikorlar ve sIL-2 reseptörünün araştırılması
TEZ1550Tez (Uzmanlık) -- Çukurova Üniversitesi, Adana, 1994.Kaynakça (s. 50-53) var.54 s. ; 30 cm.
Anti-chlamidial antibody levels in Behçet's disease
Bakteriolojik olarak henüz izole edilememiş olmasına rağmen. Behçet hastalığında bakteriel antijenlerin ve ısı sok proteinlerinin etyopatogenetık rolünün olabileceği bildirilmiştir. Bu çalışmada klinik ve immünolojik özellikleri bakımından Reiter sendromu ve diğer spondilartropatilerle bazı benzerlikler gösteren Behçet hastalığında klamidial enfeksiyonların rolü araştırıldı, hternasyonel Çalışma Grubu kriterlerine uygun olarak tanısı konan 33 Behçet'ti hasta ve 33 sağlıklı kontrolda serumda klamidial antikor düzeyleri solid faz enzim immunoassay yöntemi ile ölçüldü. Bu antikorların ortalama düzeyi Behçet'ti hastalarda 8.4±6.07 EUSA üniti, kontrollarda 10.3±14.21ELISA üniti olup aradaki fark önemli değildir (p>0.05). Reiter sendromunda spondilartrojenik HLA-B27 alt grupları olan B*2705, B*2701, B*2702, B*2704, B*2707 dışında kalan vakalarda bu antijenlerle kros reaktif olan (B7-Creg) B7, B40 (B60 veya B61), B22 (B54, B55, B56) ve/veya B42 grubu antijenlere raslanması ve bu grubun içinde Behçet hastalığının karakteristiği olan HLA-B5 (B*5101) in bulunmaması, bu hastalıkta farklı antijenik determinantların dolayısıyla farklı patojenlerin rolünün olabileceğini düşündürmetedir
Anti-neutrophil cytoplasmic antibodies in familial Mediterranean fever
Anti-nötrofil sitoplazmik antikorlar, belirlenmeleri için en iyi standard olarak kabul edilen immünofloresan teknikle, mikroskopik görünümlerine göre, sitoplazmik (c-ANCA) ve perinükleer (p-ANCA) olmak üzere iki şekilde tanımlanmıştır. Sıklıkla pozitif bulundukları pauci-immün nekrotizan vaskülitler dışında, differ inflamatuar hastalıklarda da görülebilirler. Akut hecmede olan 21 FMF'li hastada indirekt floresan antikor tekniğini kullanarak anti-nötrofil sitoplazmik antikorların sıklığını araştırdık. Hasta grubu ve 20 sağlıklı gönüllüden oluşan kontrol grubunda hiçbir pozitifliğe rastlamadık. Pozitif kontrol olarak, aldığımız 22 aktif lupuslu hastada antikorları %59 oranında pozitif bulduk. Henüz sebebi bilinmeyen inflamatuar bir hastalık olan FMF'de mutlak ANCA negatif ligi, patogenezinin primer nekrotizan vaskülitlerden tamamen farklı bir mekanizma ile oluşmasına ve/veya patogenezin yöneldiği hedefin farklılığına bağlı olabilir
TNF- and IL-1 levels in serum and cerebrospinal fluid in patients with multiple sclerosis
Purpose: Proinflammatory cytokines like tumor necrosis factor-alpha (TNF- ) and interleukin-1beta (IL-1ß ) enhance inflammation and may contribute to the pathogenesis of multiple sclerosis. The purpose of this study is to investigate the presence of these cytokines in multiple sclerosis (MS) patients with different clinical types and disease activity, and to determine their relationship with disability. Methods: We measured TNF- and IL-1 levels in cerebrospinal fluid (CSF) and serum samples from 22 patients with MS and 18 patients with other neurological diseases (OND) using commercially available immunoradiometric assay kits. Results: In serum, TNF- was detected in all patients, IL-1 was detected in 20 patients with MS and in 16 patients with OND. In CSF, all patients had detectable levels of both cytokines. The serum cytokine levels of patients with MS and patients with OND were not statistically different. However, in CSF, regardless of the clinical type, patients with active MS had higher levels of both cytokines compared to patients with stable MS and OND. There was no correlation between the levels of these cytokines and the disability. Conclusion: These data provide evidence that TNF- and IL-1 levels in CSF can be used as an activity criteria in MS.Purpose: Proinflammatory cytokines like tumor necrosis factor-alpha (TNF- ) and interleukin-1beta (IL-1ß ) enhance inflammation and may contribute to the pathogenesis of multiple sclerosis. The purpose of this study is to investigate the presence of these cytokines in multiple sclerosis (MS) patients with different clinical types and disease activity, and to determine their relationship with disability. Methods: We measured TNF- and IL-1 levels in cerebrospinal fluid (CSF) and serum samples from 22 patients with MS and 18 patients with other neurological diseases (OND) using commercially available immunoradiometric assay kits. Results: In serum, TNF- was detected in all patients, IL-1 was detected in 20 patients with MS and in 16 patients with OND. In CSF, all patients had detectable levels of both cytokines. The serum cytokine levels of patients with MS and patients with OND were not statistically different. However, in CSF, regardless of the clinical type, patients with active MS had higher levels of both cytokines compared to patients with stable MS and OND. There was no correlation between the levels of these cytokines and the disability. Conclusion: These data provide evidence that TNF- and IL-1 levels in CSF can be used as an activity criteria in MS
Serum ICAM-1 levels in kidney transplantation
Purpose: Intercellular adhesion molecule-1 (ICAM-1) is a member of immunoglobulin superfamily and acts as a ligand for the LFA-1 which is a leukocyte integrin. ICAM-1 has a role in the pathogenesis of various inflammatory processes and allograft rejection in kidney and heart transplantation. The aim of this study is to compare the serum ICAM-1 levels of kidney recipients with chronic rejection, recipients with functioning renal allografts and healthy controls. Methods: In this prospective study, serum ICAM-1 values of the 31 kidney transplantation patients (15 with normally functioning grafts and 16 with chronically rejected grafts) and 21 healthy controls were determined with ELISA method. Triple drug immunosuppressive regimen (cyclosporine + azathioprine + methylprednisolone) was given to the patients with kidney grafts. Results: The mean serum ICAM-1 level of the patients with chronic rejection (379.5±244.3 ng/ml) was higher than that of patients with functioning grafts (268.8±88 ng/ml). Although this difference was found to be statistically insignificant (p=0.057), it was close to the significancy limit. There was no statistically significant difference between the serum ICAM-1 levels of the patients either with chronic rejection or functioning grafts and those of healthy controls (307.3±63.6 ng/ml) (p=0.96 and p=0.07 respectively). Conclusion: Our findings suggest that, normal serum levels of ICAM-1 in patients with functioning grafts may be a result of proper immunosuppression. Elevated serum ICAM-1 levels in patients with chronic graft rejection indicate an activation in the immune system. We can conclude that serum ICAM-1 level measurement is not a specific parameter for detection of chronic renal graft rejection.Purpose: Intercellular adhesion molecule-1 (ICAM-1) is a member of immunoglobulin superfamily and acts as a ligand for the LFA-1 which is a leukocyte integrin. ICAM-1 has a role in the pathogenesis of various inflammatory processes and allograft rejection in kidney and heart transplantation. The aim of this study is to compare the serum ICAM-1 levels of kidney recipients with chronic rejection, recipients with functioning renal allografts and healthy controls. Methods: In this prospective study, serum ICAM-1 values of the 31 kidney transplantation patients (15 with normally functioning grafts and 16 with chronically rejected grafts) and 21 healthy controls were determined with ELISA method. Triple drug immunosuppressive regimen (cyclosporine + azathioprine + methylprednisolone) was given to the patients with kidney grafts. Results: The mean serum ICAM-1 level of the patients with chronic rejection (379.5±244.3 ng/ml) was higher than that of patients with functioning grafts (268.8±88 ng/ml). Although this difference was found to be statistically insignificant (p=0.057), it was close to the significancy limit. There was no statistically significant difference between the serum ICAM-1 levels of the patients either with chronic rejection or functioning grafts and those of healthy controls (307.3±63.6 ng/ml) (p=0.96 and p=0.07 respectively). Conclusion: Our findings suggest that, normal serum levels of ICAM-1 in patients with functioning grafts may be a result of proper immunosuppression. Elevated serum ICAM-1 levels in patients with chronic graft rejection indicate an activation in the immune system. We can conclude that serum ICAM-1 level measurement is not a specific parameter for detection of chronic renal graft rejection